Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models

Author(s):  
Fiore Cattaruzza ◽  
Pete Yeung ◽  
Wan-Ching Yen ◽  
Alayne Brunner ◽  
Min Wang ◽  
...  
2014 ◽  
Author(s):  
Marcus M. Fischer ◽  
Jalpa Shah ◽  
Jennifer Cain ◽  
Belinda Cancilla ◽  
James W. Evans ◽  
...  

2018 ◽  
Author(s):  
Deli Hong ◽  
Andrew J. Fritz ◽  
Kristiaan H. Finstad ◽  
Mark P. Fitzgerald ◽  
Adam L. Viens ◽  
...  

SummaryRecent studies have revealed that mutations in the transcription factor Runx1 are prevalent in breast tumors. Yet, how loss of Runx1 contributes to breast cancer (BCa) remains unresolved. We demonstrate for the first time that Runx1 represses the breast cancer stem cell (BCSC) phenotype and consequently, functions as a tumor suppressor in breast cancer. Runx1 ectopic expression in MCF10AT1 and MCF10CA1a BCa cells reduces (60%) migration, invasion and in vivo tumor growth in mouse mammary fat pad (P<0.05). Runx1 is decreased in BCSCs, and overexpression of Runx1 suppresses tumorsphere formation and reduces the BCSC population. Furthermore, Runx1 inhibits Zeb1 expression, while Runx1 depletion activates Zeb1 and the epithelial-mesenchymal transition. Mechanistically Runx1 functions as a tumor suppressor in breast cancer through repression of cancer stem cell activity. This key regulation of BCSCs by Runx1 may be shared in other epithelial carcinomas, highlighting the importance of Runx1 in solid tumors.


Author(s):  
Somdutta Roy ◽  
Kevin Martinez ◽  
Arturo Ramirez ◽  
Daniel Campton ◽  
Joshua Nordberg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document